NEU

15.1%

$16.57 neuren pharmaceuticals limited

Share Price, page-11609

First 11609 Last

Share
Profile

Follow
Investie

901 Posts.

211

03/09/24

23:07

Post #: 75514776
Share

Originally posted by Jpow: ↑

Is There Enough Revenue Growth Forecasted For Neuren Pharmaceuticals?
The only time you'd be truly comfortable seeing a P/S as steep as Neuren Pharmaceuticals' is when the company's growth is on track to outshine the industry decidedly.Taking a look back first, we see that the company's revenues underwent some rampant growth over the last 12 months. Spectacularly, three year revenue growth has also set the world alight, thanks to the last 12 months of incredible growth. Therefore, it's fair to say the revenue growth recently has been superb for the company.
Turning to the outlook, the next three years should bring diminished returns, with revenue decreasing 0.1% per year as estimated by the six analysts watching the company. Meanwhile, the broader industry is forecast to expand by 14% per annum, which paints a poor picture.
With this information, we find it concerning that Neuren Pharmaceuticals is trading at a P/S higher than the industry. Apparently many investors in the company reject the analyst cohort's pessimism and aren't willing to let go of their stock at any price.
Only the boldest would assume these prices are sustainable as these declining revenues are likely to weigh heavily on the share price eventually.What We Can Learn From Neuren Pharmaceuticals' P/S?While the price-to-sales ratio shouldn't be the defining factor in whether you buy a stock or not, it's quite a capable barometer of revenue expectations.
For a company with revenues that are set to decline in the context of a growing industry, Neuren Pharmaceuticals' P/S is much higher than we would've anticipated.
Right now we aren't comfortable with the high P/S as the predicted future revenue decline likely to impact the positive sentiment that's propping up the P/S. This places shareholders' investments at significant risk and potential investors in danger of paying an excessive premium.

Expand

What is this bs and who wrote it? Revenue will shrink? So no release in Canada, Europe, Japan or elsewhere ever of Daybue.. Not going to test the rest of the US market? No new patients will be diagnosed ever and you wont see increased diagnosis now there is a treatement (like you do for other rare diseases?)

NEU Price at posting: $14.07 Sentiment: Buy Disclosure: Held
13 Upvote

0 Great analysis

Reply

Top Stories

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

IMU

Imugene kicks off Australian trial for blood cancer treatment

Trump Victory Sends Bitcoin Surging Above $75K – Is $100K Next?

FG1

Flynn Gold reaches milestone exploration target for Golden Ridge

Trump is President Again: What Does This Mean for Crypto?

Week 45 Wrap: Combat sports usher in Trump 2.0 – or is it male insecurity?; RBA boring; Propane suggests China alive

MMI

Metro Mining inks bauxite offtake contracts into 2026 with Chinese m

UBI

Universal Biosensors flat despite fresh deal with US medical product distributor

HotCopper Highlights: Your most watched and most discussed stocks this week

First 11609 Last

Add NEU (ASX) to my watchlist

(20min delay)
Last $16.57		Change 2.170(15.1%)		Mkt cap ! $2.117B

Open	High	Low	Value	Volume
$14.85	$16.67	$14.60	$24.77M	1.544M

Buyers (Bids)

No.	Vol.	Price($)
1	1500	$16.52

Sellers (Offers)

Price($)	Vol.	No.
$16.57	1717	1

View Market Depth

No.	Vol.	Price($)
1	250	16.480
1	300	16.470
1	500	16.400
1	3	16.270
1	150	16.200

Price($)	Vol.	No.
16.570	1717	1
16.600	2001	1
16.620	2306	2
16.650	2000	1
16.660	250	1

Last trade - 16.10pm 08/11/2024 (20 minute delay)

NEU (ASX) Chart

Share Price, page-11609

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

Imugene kicks off Australian trial for blood cancer treatment

Trump Victory Sends Bitcoin Surging Above $75K – Is $100K Next?

Flynn Gold reaches milestone exploration target for Golden Ridge

Trump is President Again: What Does This Mean for Crypto?

Week 45 Wrap: Combat sports usher in Trump 2.0 – or is it male insecurity?; RBA boring; Propane suggests China alive

Metro Mining inks bauxite offtake contracts into 2026 with Chinese m

Universal Biosensors flat despite fresh deal with US medical product distributor

HotCopper Highlights: Your most watched and most discussed stocks this week

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Share Price, page-11609

Top Stories

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

Imugene kicks off Australian trial for blood cancer treatment

Trump Victory Sends Bitcoin Surging Above $75K – Is $100K Next?

Flynn Gold reaches milestone exploration target for Golden Ridge

Trump is President Again: What Does This Mean for Crypto?

Week 45 Wrap: Combat sports usher in Trump 2.0 – or is it male insecurity?; RBA boring; Propane suggests China alive

Metro Mining inks bauxite offtake contracts into 2026 with Chinese m

Universal Biosensors flat despite fresh deal with US medical product distributor

HotCopper Highlights: Your most watched and most discussed stocks this week

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News